Gold tier: mechanically validated evidence, with its primary source.
64 evidence items · page 1 / 3
1 sensitivityDetectable HBV-DNA at baseline had sensitivity of 1.00 and specificity of 0.80 for predicting HBsAg seroclearance.
Côte d'Ivoirehépatite Bpublished 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156
33.3 %Among 66 HBsAg-positive patients, 33.3% were inactive HBV carriers.
Côte d'Ivoirehépatite B · VIH/sidaobserved 2006published 2012World journal of hepatologyeurope_pmcdocument of 13 observations
13.4 %HBsAg prevalence was 13.4% among 491 adult HIV patients in Abidjan.
Côte d'Ivoirehépatite B · VIH/sidaobserved 2006published 2012World journal of hepatologyeurope_pmcdocument of 13 observations
13.2 per_100_person_yearsAfter a median 2.0 year follow-up, the incidence rate of serious HIV-related events was 13.2 per 100 person-years among HIV-HBV co-infected patients.
Côte d'Ivoirehépatite B · VIH/sidapublished 2017The American journal of tropical medicine and hygieneeurope_pmcdocument of 7 observationsDOI 10.4269/ajtmh.16-1016
86.6 %Cumulative proportion of undetectable HBV-DNA was 86.6% in patients with baseline pcG1896A mutation and 66.9% in those without, among antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.
Côte d'Ivoirehépatite Bpublished 2018Journal of viral hepatitiseurope_pmcdocument of 7 observationsDOI 10.1111/jvh.12914
7.3 %HBsAg positivity prevalence among first-time female blood donors in Abidjan was 7.3% in 1992–1994 and 7.1% in 2010–2012.
Côte d'Ivoirehépatite Bobserved 1992–1994published 2018Open forum infectious diseaseseurope_pmcdocument of 12 observations
75.2 %Among 161 antiretroviral-naïve HIV-HBV coinfected patients in Côte d'Ivoire, 121 (75.2%) had detectable HBV DNA.
Côte d'Ivoirehépatite B · VIH/sidapublished 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156
23 %Among ART-naive HIV-1-infected adults in Côte d'Ivoire, 23% had never been exposed to HBV.
Côte d'Ivoirehépatite B · VIH/sidapublished 2010Antiviral therapyeurope_pmcdocument of 7 observations
42 %Among ART-naive HIV-1-infected adults in Côte d'Ivoire, 42% had isolated anti-HBc.
Côte d'Ivoirehépatite B · VIH/sidapublished 2010Antiviral therapyeurope_pmcdocument of 7 observations
21.3 %Occult HBV infection prevalence was 21.3% among HBsAg-negative, anti-HBcAb-positive, anti-HBsAb-negative patients with detectable HBV DNA.
Côte d'Ivoirehépatite B · VIH/sidaobserved 2006published 2012World journal of hepatologyeurope_pmcdocument of 13 observations
6.6 %The overall cumulative proportion of HBsAg seroclearance was 6.6% (n = 10).
Côte d'Ivoirehépatite Bpublished 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156
98.9 %Among 93 patients tested, 92 (98.9%) harbored HBV genotype E.
Côte d'Ivoirehépatite Bpublished 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156
8.5 %Among 791 HIV-infected patients in West Africa, 67 (8.5%) were HBsAg positive.
Côte d'Ivoirehépatite B · VIH/sidaobserved 2012published 2017BMC infectious diseaseseurope_pmcdocument of 7 observations
4.37 adjusted_IRRHBsAg-positive individuals with HBV-DNA ≥2000 IU/mL had an adjusted incidence rate ratio for mortality of 4.37 (95% CI = 0.98–13.02) at CD4+ counts 351–500/mm³ compared to HBsAg-negative individuals.
Côte d'Ivoirehépatite B · VIH/sidapublished 2021Antiviral therapyeurope_pmcdocument of 4 observations
20.5 %Among 161 antiretroviral-naïve HIV-HBV coinfected patients in Côte d'Ivoire, 33 (20.5%) were HBeAg positive.
Côte d'Ivoirehépatite B · VIH/sidapublished 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156
51.1 %Only 51.1% of the AEB victims were correctly vaccinated against hepatitis B.
Côte d'Ivoirehépatite Bobserved January 2000 to December 2005published 2007Medecine et maladies infectieuseseurope_pmcdocument of 11 observations
10.8 %HBsAg positivity prevalence among first-time blood donors in Abidjan remained stable at 10.8% in 1992–1994 and 11.1% in 2010–2012.
Côte d'Ivoirehépatite Bobserved 1992–1994published 2018Open forum infectious diseaseseurope_pmcdocument of 12 observations
97.7 %97.7% of 86 antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire harboured HBV genotype E at ARV-initiation.
Côte d'Ivoirehépatite Bpublished 2018Journal of viral hepatitiseurope_pmcdocument of 7 observationsDOI 10.1111/jvh.12914
30.3 %Among 66 HBsAg-positive patients, 30.3% had HBeAg-negative hepatitis.
Côte d'Ivoirehépatite B · VIH/sidaobserved 2006published 2012World journal of hepatologyeurope_pmcdocument of 13 observations
0 seroconversionsNo HIV and HBV seroconversion was observed after a 3-month follow-up among rape victims receiving antiretroviral chemoprophylaxis in Abidjan.
Côte d'Ivoirehépatite B · VIH/sidapublished 2015Medecine et maladies infectieuseseurope_pmcdocument of 3 observations
0 %Cumulative proportion of HBsAg seroclearance was 0% in patients with baseline pcG1896A mutation and 36.9% in those without, among antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.
Côte d'Ivoirehépatite Bpublished 2018Journal of viral hepatitiseurope_pmcdocument of 7 observationsDOI 10.1111/jvh.12914
59.3 %Baseline pcG1896A mutation was identified in 51 (59.3%) of 86 antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.
Côte d'Ivoirehépatite Bpublished 2018Journal of viral hepatitiseurope_pmcdocument of 7 observationsDOI 10.1111/jvh.12914
25 monthsThe median follow-up duration was 25 months (interquartile range 19–31 months) among HBeAg-negative HIV/HBV co-infected patients in Côte d'Ivoire.
Côte d'Ivoirehépatite B · VIH/sidapublished 2019Transactions of the Royal Society of Tropical Medicine and Hygieneeurope_pmcdocument of 4 observations
10,000 copies/mLChronic HBeAg-negative HBV infection phase was defined as HBV DNA ≤10,000 copies/mL and normal alanine aminotransferase (ALT).
Côte d'Ivoirehépatite Bpublished 2019Transactions of the Royal Society of Tropical Medicine and Hygieneeurope_pmcdocument of 4 observations
135 individualsAmong 190 HBsAg-positive participants, 135 (71%) had HBV DNA+.
Côte d'Ivoirehépatite Bpublished 2021Antiviral therapyeurope_pmcdocument of 4 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.